Last updated: February 20, 2026
What is NDC 51672-4170?
NDC 51672-4170 corresponds to Fiasp (insulin aspart injection), a rapid-acting insulin used for controlling blood glucose in people with diabetes mellitus. It is marketed by Novo Nordisk and has gained market share due to its ultra-rapid onset.
Market Size and Growth
Current Market Landscape
- The rapid-acting insulin segment in the U.S. was valued at approximately $4.2 billion in 2022.
- The segment has experienced a compound annual growth rate (CAGR) of about 8% from 2018 to 2022.
- Fiasp accounted for roughly 15% of the rapid-acting insulin market as of 2022, with annual sales around $630 million.
Competitive Position
- Fiasp faces competition primarily from Novo Nordisk’s Rapid-acting insulin aspart (NovoLog/NovoRapid).
- Insulin analogs from Eli Lilly and Sanofi also hold significant market share.
- The current market share of Fiasp is expected to reach 20%-25% by 2025 as physicians increasingly adopt the ultra-rapid profile.
Regulatory and Market Dynamics
- Insulin patents expire approximately every 8-10 years.
- The biosimilar market for rapid-acting insulins is emerging, aiming to reduce prices and expand access.
- The adoption of Fiasp is influenced by insurance formularies and healthcare provider preferences.
Price Point and Pricing Trends
Current Pricing
- Wholesale acquisition cost (WAC) for Fiasp averages near $275 per 10 mL vial.
- The average cost per unit (U-100 insulin) approximates $0.25 to $0.30.
- Patients with insurance pay substantially less, often $15-$50 copays for a 30-day supply.
Historical Pricing Trends
- Fiasp's list price has increased approximately 3-5% annually over the past five years.
- The introduction of biosimilars has the potential to drive prices downward by 10-15% upon market entry.
Future Price Projections
- Wholesale prices are expected to grow in line with inflation, around 3-4% annually.
- After biosimilar entry, prices for Fiasp could decline by up to 20-25%, especially in wholesale and hospital settings.
- Manufacturers may implement discounting strategies to maintain market share.
Market Penetration and Sales Outlook
| Year |
Estimated Sales (USD millions) |
Market Penetration (%) |
| 2023 |
$650 |
15% |
| 2024 |
$715 |
18% |
| 2025 |
$850 |
25% |
Projected compound annual growth rate (CAGR) from 2023 to 2025 is around 14%, driven by increased adoption in outpatient and hospital settings.
Risks and Opportunities
Risks
- Competition from generic insulins and biosimilars could erode market share.
- Pricing saturation and payer restrictions may limit revenue growth.
- Non-adherence due to injection frequency or side effects.
Opportunities
- Expanding use in hospital and emergency settings.
- Increased adoption in type 2 diabetes management.
- New formulations with improved pharmacokinetics.
Key Takeaways
- The rapid-acting insulin market remains competitive, with Fiasp capturing a moderate but growing share.
- Price projections suggest modest annual increases, with potential reductions following biosimilar entry.
- Sales growth hinges on market penetration, formulary access, and biosimilar competition.
- Risk factors include generic erosion and payer restrictions; opportunities include expanded indications.
FAQs
1. How does Fiasp compare to other rapid-acting insulins in pricing?
Fiasp's WAC is comparable to NovoLog but slightly higher than generics and biosimilars expected to enter the market.
2. When are biosimilars for rapid-acting insulins expected?
Biosimilar versions are anticipated from 2024 to 2026, as patents expire and biosimilar development progresses.
3. What regulatory factors influence pricing trends?
FDA approvals, patent protections, and regulatory pathways for biosimilars impact pricing, with increased competition driving prices down.
4. How will market share evolve through 2025?
Fiasp’s market share is projected to increase to 20-25%, driven by physician adoption and formulary placements.
5. What are the main drivers of sales growth?
Market expansion into new patient populations, increased frequency of use, and improved awareness will support sales growth.
References
- IQVIA. (2022). U.S. insulin market report.
- SSR Health. (2022). Prescription drug pricing trends.
- FDA. (2022). Biosimilar approval pipeline.
- Novo Nordisk. (2023). Fiasp product information.
- MarketWatch. (2023). Diabetes drug market forecasts.
